Adial Pharmaceuticals, Inc. announced it has been awarded a key patent combining the use of the Company's proprietary genetic diagnostic to detect select genotypes for genetically target treatment of alcohol use disorder (AUD) and opioid use disorder (OUD) with the Company's lead investigational new drug product AD04. The recently awarded patent further enhances Adial Pharmaceuticals' position at the forefront of personalized medicine in addiction therapy. Recognizing that every patient?s genetic makeup is different, the proprietary diagnostic tool is designed to predict which patients are most likely to benefit from AD04 treatment.